Avita is seen as a growth company, therefore the market expects to see growth in procedure numbers.
The market got scared when the procedures volumes slightly decreased last quarter and therefore were thinking recell was somehow not a good product and not gaining widespread adaptation.
This announcement should reassure everyone, and it is just a matter of time before recell becomes the new standard of care in all of its indications.
AVH on NASDAQ, page-700
-
- There are more pages in this discussion • 244 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.63 |
Change
0.160(6.48%) |
Mkt cap ! $179.0M | |||
| Open | High | Low | Value | Volume |
| $2.54 | $2.64 | $2.54 | $874.2K | 336.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3056 | $2.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.63 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |